Anifrolumab in the Real-World Management of Systemic Lupus Erythematosus
Episode Summary
Real-world data show about one-quarter of lupus patients achieve six-month remission with anifrolumab, supporting earlier targeted therapy, steroid reduction, and evolving care pathways for systemic lupus erythematosus.